ipilimumab,pembrolizumab,axitinib,nivolumab,lenvatinib,Sunitinib
bms,merck,eisai,pfizer
['ipilimumab', 'rcc,(-irccs),(-srcc),(-urcc)']
awesome discussion from dr. highlighting the duration of response with io-io and io-tki in 1st line mrcc. perhaps ipilimumab is the key for a longer benefit. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer